Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) had its price objective boosted by equities researchers at Piper Sandler from $4.00 to $6.00 in a research report issued on Friday,Benzinga reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback